Ono Pharmaceutical Co., Ltd. Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study ofromVIMZA in Patients with Tenosynovial Giant Cell Tumor at the European Society for Medical Oncology Congress 2025

marketscreener
2025.10.18 13:10
portai
I'm PortAI, I can summarize articles.

Ono Pharmaceutical Co., Ltd. will present the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib for treating tenosynovial giant cell tumor (TGCT) at the 2025 European Society for Medical Oncology Congress in Berlin. The study evaluates vimseltinib's effectiveness in patients where surgical removal is not an option, with participants receiving either the drug or a placebo in a two-part study. Results include objective response rates and safety evaluations based on independent reviews.

Source: marketscreener The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.